The signaling pathways of atherosclerosis regulated by Taohong Siwu Decoction

IF 7.5 2区 医学 Q1 INTEGRATIVE & COMPLEMENTARY MEDICINE
Chinese Journal of Natural Medicines Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI:10.1016/S1875-5364(26)61103-X
Kaijie Yan , Sihe Gong , Yanni Li , Zhonghong Shi , Yimin Bao , Jing Leng , Ke Ning
{"title":"The signaling pathways of atherosclerosis regulated by Taohong Siwu Decoction","authors":"Kaijie Yan ,&nbsp;Sihe Gong ,&nbsp;Yanni Li ,&nbsp;Zhonghong Shi ,&nbsp;Yimin Bao ,&nbsp;Jing Leng ,&nbsp;Ke Ning","doi":"10.1016/S1875-5364(26)61103-X","DOIUrl":null,"url":null,"abstract":"<div><div>Taohong Siwu Decoction (THSWD), a traditional Chinese medicinal formulation, has been demonstrated to significantly modulate key signaling pathways implicated in atherosclerosis (AS). This review examines the complex mechanisms through which THSWD influences critical pathways, including nuclear factor kappa-B (NF-<em>κ</em>B), phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT), Toll-like receptor 4 (TLR4), mitogen-activated protein kinase (MAPK), and mammalian target of rapamycin (mTOR), that play pivotal roles in AS pathogenesis. By synthesizing experimental evidence and existing literature, the review summarizes how THSWD and its bioactive constituents regulate these signaling cascades to ameliorate AS. Furthermore, it highlights the distinctive therapeutic advantages of traditional Chinese medicine (TCM) compounds in managing chronic diseases driven by multi-target and multifactorial mechanisms. Analyzing disease targets from the perspective of signaling pathways enhances the scientific validation of clinical efficacy for such formulations, thereby offering novel insights for future research.</div></div>","PeriodicalId":10002,"journal":{"name":"Chinese Journal of Natural Medicines","volume":"24 3","pages":"Pages 279-288"},"PeriodicalIF":7.5000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Natural Medicines","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S187553642661103X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/2 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Taohong Siwu Decoction (THSWD), a traditional Chinese medicinal formulation, has been demonstrated to significantly modulate key signaling pathways implicated in atherosclerosis (AS). This review examines the complex mechanisms through which THSWD influences critical pathways, including nuclear factor kappa-B (NF-κB), phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (AKT), Toll-like receptor 4 (TLR4), mitogen-activated protein kinase (MAPK), and mammalian target of rapamycin (mTOR), that play pivotal roles in AS pathogenesis. By synthesizing experimental evidence and existing literature, the review summarizes how THSWD and its bioactive constituents regulate these signaling cascades to ameliorate AS. Furthermore, it highlights the distinctive therapeutic advantages of traditional Chinese medicine (TCM) compounds in managing chronic diseases driven by multi-target and multifactorial mechanisms. Analyzing disease targets from the perspective of signaling pathways enhances the scientific validation of clinical efficacy for such formulations, thereby offering novel insights for future research.
桃红四物汤调控动脉粥样硬化的信号通路。
桃红四物汤(THSWD)是一种中药制剂,已被证明可以显著调节动脉粥样硬化(AS)的关键信号通路。本文综述了THSWD影响关键通路的复杂机制,包括在AS发病中起关键作用的核因子κ b (NF-κB)、磷脂酰肌醇3-激酶(PI3K)/丝氨酸-苏氨酸激酶(AKT)、toll样受体4 (TLR4)、丝裂原活化蛋白激酶(MAPK)和哺乳动物雷帕霉素靶点(mTOR)。通过综合实验证据和现有文献,本文综述了THSWD及其生物活性成分如何调节这些信号级联以改善AS。此外,它突出了中药化合物在治疗多靶点和多因子机制驱动的慢性疾病方面的独特治疗优势。从信号通路的角度分析疾病靶点,增强了对此类制剂临床疗效的科学验证,从而为未来的研究提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Chinese Journal of Natural Medicines
Chinese Journal of Natural Medicines INTEGRATIVE & COMPLEMENTARY MEDICINE-PHARMACOLOGY & PHARMACY
CiteScore
7.50
自引率
4.30%
发文量
2235
期刊介绍: The Chinese Journal of Natural Medicines (CJNM), founded and sponsored in May 2003 by China Pharmaceutical University and the Chinese Pharmaceutical Association, is devoted to communication among pharmaceutical and medical scientists interested in the advancement of Traditional Chinese Medicines (TCM). CJNM publishes articles relating to a broad spectrum of bioactive natural products, leading compounds and medicines derived from Traditional Chinese Medicines (TCM). Topics covered by the journal are: Resources of Traditional Chinese Medicines; Interaction and complexity of prescription; Natural Products Chemistry (including structure modification, semi-and total synthesis, bio-transformation); Pharmacology of natural products and prescription (including pharmacokinetics and toxicology); Pharmaceutics and Analytical Methods of natural products.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书